COSCIENS Biopharma Inc. (CSCI) - Total Assets
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) holds total assets worth $27.56 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See latest COSCIENS Biopharma Inc. stock price today for real-time trading data and today's change.
COSCIENS Biopharma Inc. - Total Assets Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s total assets have evolved over time, based on quarterly financial data. Also see cash flow conversion of COSCIENS Biopharma Inc. for how efficiently the company converts equity into cash flow.
COSCIENS Biopharma Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
COSCIENS Biopharma Inc.'s total assets of $27.56 Million consist of 68.4% current assets and 31.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.7% |
| Accounts Receivable | $2.47 Million | 7.1% |
| Inventory | $2.69 Million | 7.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CSCI net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: COSCIENS Biopharma Inc.'s current assets represent 68.4% of total assets in 2024, an increase from 17.7% in 1996.
- Cash Position: Cash and equivalents constituted 46.7% of total assets in 2024, up from 5.4% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 32.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 7.7% of total assets.
COSCIENS Biopharma Inc. Competitors by Total Assets
Key competitors of COSCIENS Biopharma Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Seegene Inc
KQ:096530
|
Korea | ₩1.22 Trillion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.53 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NervGen Pharma Corp
V:NGEN
|
Canada | CA$13.08 Million |
COSCIENS Biopharma Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 3.36 | 3.93 |
| Quick Ratio | 2.65 | 3.05 | 3.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.97 Million | $23.31 Million | $5.27 Million |
COSCIENS Biopharma Inc. - Advanced Valuation Insights
This section examines the relationship between COSCIENS Biopharma Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.17 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 47.7% |
| Total Assets | $35.07 Million |
| Market Capitalization | $8.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values COSCIENS Biopharma Inc.'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: COSCIENS Biopharma Inc.'s assets grew by 47.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual total assets of COSCIENS Biopharma Inc. from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $35.07 Million | +47.69% |
| 2023-12-31 | $23.75 Million | -14.60% |
| 2022-12-31 | $27.80 Million | +14.17% |
| 2021-12-31 | $24.35 Million | +6.26% |
| 2020-12-31 | $22.92 Million | +9.78% |
| 2019-12-31 | $20.88 Million | +12.27% |
| 2018-12-31 | $18.59 Million | -15.92% |
| 2017-12-31 | $22.11 Million | +12.62% |
| 2016-12-31 | $19.64 Million | +73.51% |
| 2015-12-31 | $11.32 Million | +70.98% |
| 2014-12-31 | $6.62 Million | +38.26% |
| 2013-12-31 | $4.79 Million | +22.55% |
| 2012-12-31 | $3.91 Million | -4.38% |
| 2011-12-31 | $4.09 Million | +44.89% |
| 2010-12-31 | $2.82 Million | +6.55% |
| 2009-12-31 | $2.65 Million | -2.04% |
| 2008-12-31 | $2.70 Million | -41.69% |
| 2007-12-31 | $4.63 Million | +161.76% |
| 2006-12-31 | $1.77 Million | -15.03% |
| 2005-12-31 | $2.08 Million | +45.75% |
| 2004-12-31 | $1.43 Million | +47.62% |
| 2003-12-31 | $968.03K | +136.15% |
| 2002-12-31 | $409.92K | +74.80% |
| 2001-12-31 | $234.50K | +19.54% |
| 2000-12-31 | $196.16K | -2.48% |
| 1999-12-31 | $201.16K | -38.10% |
| 1998-12-31 | $324.95K | -96.45% |
| 1997-12-31 | $9.15 Million | -32.55% |
| 1996-12-31 | $13.57 Million | -- |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more